XTL Biopharmaceuticals Ltd. (FRA:H2K2)

Germany flag Germany · Delayed Price · Currency is EUR
0.5200
-0.0150 (-2.80%)
At close: Jan 9, 2026
-70.45%
Market Cap5.68M
Revenue (ttm)824.25K
Net Income (ttm)-5.37M
Shares Outn/a
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume730
Open0.5450
Previous Close0.5350
Day's Range0.5200 - 0.5450
52-Week Range0.4440 - 4.0000
Betan/a
RSI38.49
Earnings DateMar 12, 2026

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1993
Employees 10
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol H2K2
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.